Skip to content

Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias

Transdermal Radiofrequency (V ERASER) Versus Polidocanol Sclerotherapy for the Treatment of Reticular Veins and Telangiectasias: A Randomized Controlled Trial (TYPER Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06962813
Acronym
TYPER
Enrollment
46
Registered
2025-05-08
Start date
2023-01-10
Completion date
2025-04-10
Last updated
2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telangiectasias, Varicose Veins Leg

Keywords

radiofrequency, sclerotherapy, varicose veins

Brief summary

This study tested V Eraser, Transdermal radiofrequency versus polidocanol sclerotherapy for the treatment of reticular veins and telangiectasia of the legs

Detailed description

Chronic Venous Disease causes symptoms such as pain, edema, and skin manifestations, including telangiectasias and varicose veins. Sclerotherapy with polidocanol is the gold standard treatment; however, technologies such as laser devices and transdermal radiofrequency are also available. The V Eraser, a device that combines transdermal radiofrequency and sclerotherapy, was developed to treat these conditions. Methods: This was a prospective, randomized, and comparative study comparing V Eraser with sclerotherapy for the treatment of telangiectasias and reticular veins. Forty-one patients were randomized to either V Eraser or polidocanol sclerotherapy and underwent a single treatment session. Efficacy was assessed using the Aberdeen Varicose Vein Questionnaire and vessel clearance analysis in pre- and post-treatment images.

Interventions

PROCEDURERadiofrequency V Eraser

standar of care sclerotherapy

Sponsors

Science Valley Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

2 arm parallel study

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients willing to sign informed consent * Patients from 18 to 80 years old with CVD classified as CEAP clinical classes C1 to C5, but only telangiectasias and reticular veins not connected to larger varicosities

Exclusion criteria

* Patients with great saphenous or small saphenous vein insufficiency. * Patients with allergies to polidocanol * Patients with contraindications to treat varicose veins

Design outcomes

Primary

MeasureTime frameDescription
Photographic analysis30 daysImage analysis of photos was performed on day 30. Using the ImageJ software, two blinded evaluators analyzed the pre- and post-procedure photographs, measuring the vessel lengths in both images
Aberdeen AVVQ questionnaire30 daysThe Aberdeen Varicose Vein Questionnaire (AVVQ) was applied on day 30

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026